Announcements Trials
Browse Landscape

Phase

Phase 1 5

Status

Completed 15Unknown 5Terminated 5Recruiting 5Not yet recruiting 3Withdrawn 2Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 173Leukemia, Myeloid, Acute 152Breast Neoplasms 146Neoplasms 143Neoplasm Metastasis 142Colorectal Neoplasms 137Recurrence 105Ovarian Neoplasms 101Pancreatic Neoplasms 83Advanced Solid Tumor 82Lung Neoplasms 81Multiple Myeloma 77Prostatic Neoplasms 75Advanced Solid Tumors 74Stomach Neoplasms 73Squamous Cell Carcinoma of Head and Neck 72Carcinoma, Hepatocellular 68Glioblastoma 65Melanoma 64Lymphoma, Non-Hodgkin 64Triple Negative Breast Neoplasms 59Lymphoma, B-Cell 55Endometrial Neoplasms 54Myelodysplastic Syndromes 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Lymphoma 52Glioma 51Brain Neoplasms 46Carcinoma, Renal Cell 44Hematologic Neoplasms 43

Interventions

Injections 2Drug Therapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × Advanced Malignancies × Clear all
NCT06038058 2025-12-30

A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies

BioRay Pharmaceutical Co., Ltd.

Phase 1 Recruiting
164 enrolled

Advanced Malignancies

NCT06937957 2025-11-21

A Study of BR111 in Patients With Advanced Malignancies

BioRay Pharmaceutical Co., Ltd.

Phase 1 Recruiting
166 enrolled

Advanced Malignancies

NCT06717880 2025-02-12

A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1 Recruiting
260 enrolled

Advanced Malignancies

NCT04651348 2024-11-20

A Clinical Study of MIL95 in Advanced Malignancies.

Beijing Mabworks Biotech Co., Ltd.

Phase 1 Recruiting
58 enrolled

Advanced Malignancies

NCT06468098 2024-07-18

A Study of IBI363 in Subjects With Advanced Malignancies

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Recruiting
556 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡